Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $2.89B.
ENTERPRISE VALUE (EV)
$2.89B
Denali Therapeutics Inc.
Market Cap
$3.10B
Enterprise Value (EV)
$2.89B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Denali Therapeutics Inc. (DNLI) | $3.10B | $2.89B |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.08B | $3.04B |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.02B | $3.10B |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.00B | $2.87B |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.22B | $3.10B |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.32B | $3.20B |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.32B | $2.28B |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.86B | $2.20B |
| CareDx, Inc (CDNA)vs › | $3.38B | $3.02B |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.39B | $3.08B |
Market Cap
$3.10B
Total Debt
$0.00
Cash
$205.33M
Enterprise Value
$2.89B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
